Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Schachter

Showing results (101-110 of 153) with videos related to

Pageof 16
Sort By:
Neoplasia (New York, N.Y.)|June 17, 2014
CEACAM1 promotes melanoma cell growth through Sox-2Rona Ortenberg, Gilli Galore-Haskel, Ilanit Greenberg, et al.
Journal for Immunotherapy of Cancer|March 11, 2020
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patientsOrit Itzhaki, Elad Jacoby, Abraham Nissani, et al.
American Journal of Hematology|September 7, 2018
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemiaElad Jacoby, Bella Bielorai, Abraham Avigdor, et al.
Cancer Immunology, Immunotherapy : CII|September 11, 2019
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanomaJason Roszik, Ettai Markovits, Paula Dobosz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)Jean-Jacques Grob, Rene Gonzalez, Nicole Basset-Seguin, et al.
Journal of the National Cancer Institute|November 15, 2023
Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approachShirly Grynberg, Marilena Vered, Ronnie Shapira-Frommer, et al.
Cells|April 12, 2022
Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell MalignanciesKatia Beider, Orit Itzhaki, Jacob Schachter, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 10, 2023
PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapyEyal Mor, Gal Schtrechman, Eran Nizri, et al.
Dermatology and Therapy|September 24, 2021
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629Brett G M Hughes, Rene Gonzalez Mendoza, Nicole Basset-Seguin, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 16

Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
Neoplasia (New York, N.Y.)|June 17, 2014
CEACAM1 promotes melanoma cell growth through Sox-2Rona Ortenberg, Gilli Galore-Haskel, Ilanit Greenberg, et al.
Journal for Immunotherapy of Cancer|March 11, 2020
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patientsOrit Itzhaki, Elad Jacoby, Abraham Nissani, et al.
American Journal of Hematology|September 7, 2018
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemiaElad Jacoby, Bella Bielorai, Abraham Avigdor, et al.
Cancer Immunology, Immunotherapy : CII|September 11, 2019
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanomaJason Roszik, Ettai Markovits, Paula Dobosz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)Jean-Jacques Grob, Rene Gonzalez, Nicole Basset-Seguin, et al.
Journal of the National Cancer Institute|November 15, 2023
Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approachShirly Grynberg, Marilena Vered, Ronnie Shapira-Frommer, et al.
Cells|April 12, 2022
Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell MalignanciesKatia Beider, Orit Itzhaki, Jacob Schachter, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 10, 2023
PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapyEyal Mor, Gal Schtrechman, Eran Nizri, et al.
Dermatology and Therapy|September 24, 2021
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629Brett G M Hughes, Rene Gonzalez Mendoza, Nicole Basset-Seguin, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 16